|
1
|
Kim JS, Kim YG, Pyo M, Lee HK, Hong JT,
Kim Y and Han SB: Adoptive cell therapy of melanoma with
cytokine-induced killer cells. Immune Netw. 15:58–65. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ko JM and Fisher DE: A new era: Melanoma
genetics and therapeutics. J Pathol. 223:241–250. 2011. View Article : Google Scholar
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oshita C, Takikawa M, Kume A, Miyata H,
Ashizawa T, Iizuka A, Kiyohara Y, Yoshikawa S, Tanosaki R, Yamazaki
N, et al: Dendritic cell-based vaccination in metastatic melanoma
patients: Phase II clinical trial. Oncol Rep. 28:1131–1138.
2012.PubMed/NCBI
|
|
5
|
Nakai N, Hartmann G, Kishimoto S and Katoh
N: Dendritic cell vaccination in human melanoma: Relationships
between clinical effects and vaccine parameters. Pigment Cell
Melanoma Res. 23:607–619. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hussein MR: Dendritic cells and melanoma
tumorigenesis: An insight. Cancer Biol Ther. 4:501–505. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tagliamonte M, Petrizzo A, Tornesello ML,
Buonaguro FM and Buonaguro L: Antigen-specific vaccines for cancer
treatment. Hum Vaccin Immunother. 10:3332–3346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ranieri E, Kierstead LS, Zarour H,
Kirkwood JM, Lotze MT, Whiteside T and Storkus WJ: Dendritic
cell/peptide cancer vaccines: Clinical responsiveness and epitope
spreading. Immunol Invest. 29:121–125. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hightower LE: Heat shock, stress proteins,
chaperones, and proteotoxicity. Cell. 66:191–197. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Srivastava PK: Peptide-binding heat shock
proteins in the endoplasmic reticulum: Role in immune response to
cancer and in antigen presentation. Adv Cancer Res. 62:153–177.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sherman M and Multhoff G: Heat shock
proteins in cancer. Ann NY Acad Sci. 1113:192–201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao Y, Chen X, Gao W, Yang Y, Ma H and Ren
X: A new purification method for enhancing the immunogenicity of
heat shock protein 70-peptide complexes. Oncol Rep. 28:1977–1983.
2012.PubMed/NCBI
|
|
13
|
Li Y, Zhang L, Wang S, Shi P and Qu W:
Optimizing dendritic cell preparation for fusion with melanoma
cells. Iran J Immunol. 11:166–176. 2014.PubMed/NCBI
|
|
14
|
Powell KL, Stephens AS and Ralph SJ:
Development of a potent melanoma vaccine capable of stimulating
CD8(+) T-cells independently of dendritic cells in a mouse model.
Cancer Immunol Immunother. 64:861–872. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Soo JK, Ross AD and Bennett DC: Isolation
and culture of melanoma and naevus cells and cell lines. Methods
Mol Biol. 731:141–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thurner B, Röder C, Dieckmann D, Heuer M,
Kruse M, Glaser A, Keikavoussi P, Kämpgen E, Bender A and Schuler
G: Generation of large numbers of fully mature and stable dendritic
cells from leukapheresis products for clinical application. J
Immunol Methods. 223:1–15. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grossmann KF and Margolin K: Long-term
survival as a treatment benchmark in melanoma: Latest results and
clinical implications. Ther Adv Med Oncol. 7:181–191. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Min L and Hodi FS: Anti-PD1 following
ipilimumab for mucosal melanoma: Durable tumor response associated
with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res.
2:15–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Merelli B, Massi D, Cattaneo L and Mandalà
M: Targeting the PD1/PD-L1 axis in melanoma: Biological rationale,
clinical challenges and opportunities. Crit Rev Oncol Hematol.
89:140–165. 2014. View Article : Google Scholar
|
|
20
|
Kurtz DM and Gambhir SS: Tracking cellular
and immune therapies in cancer. Adv Cancer Res. 124:257–296. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chiang CL, Coukos G and Kandalaft LE:
Whole tumor antigen vaccines: Where are we? Vaccines (Basel).
3:344–372. 2015. View Article : Google Scholar
|
|
22
|
Nestle FO, Alijagic S, Gilliet M, Sun Y,
Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of
melanoma patients with peptide- or tumor lysate-pulsed dendritic
cells. Nat Med. 4:328–332. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thurner B, Haendle I, Röder C, Dieckmann
D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von
den Driesch P, et al: Vaccination with mage-3A1 peptide-pulsed
mature, monocyte-derived dendritic cells expands specific cytotoxic
T cells and induces regression of some metastases in advanced stage
IV melanoma. J Exp Med. 190:1669–1678. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schneble EJ, Yu X, Wagner TE and Peoples
GE: Novel dendritic cell-based vaccination in late stage melanoma.
Hum Vaccin Immunother. 10:3132–3138. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gong J, Nikrui N, Chen D, Koido S, Wu Z,
Tanaka Y, Cannistra S, Avigan D and Kufe D: Fusions of human
ovarian carcinoma cells with autologous or allogeneic dendritic
cells induce antitumor immunity. J Immunol. 165:1705–1711. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tamura Y, Peng P, Liu K, Daou M and
Srivastava PK: Immunotherapy of tumors with autologous
tumor-derived heat shock protein preparations. Science.
278:117–120. 1997. View Article : Google Scholar : PubMed/NCBI
|
